Trending topics and news in HCT and Cellular Therapy

CD155 CAR T cells used in preclinical models of leukemia and solid tumors

Xiong T, Wang G, Yu P, et al. CAR-T Cells Targeting CD155 Reduce Tumor Burden in Preclinical Models of Leukemia and Solid Tumors. Journal of Clinical Investigation. 2025; (doi: 10.1172/JCI189920).

Researchers believe that engineering chimeric antigen receptor (CAR) T cells to recognize CD155 is a novel approach that could be appropriate for both hematologic and solid tumors. The strategy not only has the potential to treat a broader population of patients, but also to curtail the staggering cost of CAR T-cell treatment. CD155 may be an attractive target for cell therapy due to its upregulation during tumor progression. In preclinical models of acute myeloid leukemia, non-small cell lung cancer, and pancreatic cancer, anti-CD155 CAR T cells demonstrated robust anti-tumor activity. Limited toxic effects were observed in murine CAR T cells aimed at mouse CD155, suggesting that the innovative treatment strategy is safe and effective.

Read More